Blocking lipid signaling to treat advanced, hormone‑resistant prostate cancer
Official title: Targeting Castration Resistant Prostate Cancer via Potent Inhibition of Signaling Lipids
Funded at Baylor College of Medicine · NIH-11170557 · Data updated 2026-11-12
This project aims to block lipid signaling with potent inhibitors to help men whose prostate cancer no longer responds to hormone therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $969,204 |
| NIH project number | 4R01CA251560-04 |
| Project ID | NIH-11170557 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with metastatic castration‑resistant prostate cancer who have progressed on standard hormone therapies would be the main candidates for related clinical efforts.
✕Less likely to help
People with early‑stage prostate cancer, women, or tumors that do not rely on lipid signaling pathways are unlikely to benefit from this work.
What this research studies
You have advanced castration‑resistant prostate cancer that keeps growing despite hormone treatments; this research targets the fats and signaling pathways cancer cells use to survive. The team is developing and testing strong inhibitors of signaling lipids and the enzymes and transcription factors (like SREBP and PI3K/Akt) that drive lipid production in tumors. Work includes laboratory and animal studies and analysis of human tumor biology, with attention to differences seen in African American patients. The goal is to find approaches that could be turned into new treatments for patients whose cancers are currently lethal.
Why it matters
Potential benefit: If successful, this could slow or stop growth of hormone‑resistant prostate tumors and lead to new treatment options for men with metastatic CRPC.
How similar studies have gone: Preclinical studies targeting lipid metabolism and PI3K/Akt pathways have slowed tumor growth in models, but clinical therapies based on this approach are still emerging.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Kaochar, Salma — Baylor College of Medicine
- Study coordinator: Kaochar, Salma
Related research
Other NIH-funded projects on the same topics.
-
Understanding how aggressive cell states emerge in castration-resistant prostate cancer
A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.
-
Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer
Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.
-
Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer
Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.
-
Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy
This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer
A cancer research effort aimed at understanding and tackling how aggressive prostate cancers become resistant to standard AR-targeted therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.